JP Morgan Maintains Neutral on Alnylam Pharmaceuticals, Raises Price Target to $170
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Jessica Fung has maintained a Neutral rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and increased the price target from $150 to $170.
February 01, 2024 | 2:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JP Morgan analyst Jessica Fung maintains a Neutral rating on Alnylam Pharmaceuticals and raises the price target from $150 to $170.
The increase in price target by a reputable analyst like Jessica Fung from JP Morgan suggests a positive outlook on the stock's value, potentially leading to short-term investor optimism and a positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100